Summary of: Kaden et al. (2026), Frontiers in Immunology

Inflammatory bowel disease (IBD), including its two main types, ulcerative colitis (UC) and Crohn’s disease (CD), is rising globally and still has no curative therapy.

IBD is commonly treated with immunomodulatory drugs or biologics that aim to reduce inflammation and disease symptoms. However, many patients experience primary non-response, loss of response over time, or eventually require surgery. A central driver of symptoms and flare severity is breakdown of the intestinal barrier: once the “wall” is compromised, microbial products can fuel a self-reinforcing inflammatory loop.

Novel therapies have the goal to target the underlying cause rather than the symptoms of the disease. They aim at the underlying microbial dysbiosis by restoring the microecology and metabolome pool such as the reduced secondary bile acids during active disease. Lithocholic acid (LCA), a microbiota-derived secondary bile acid, is markedly decreased in IBD patients, yet prior work suggests it can support intestinal barrier and cellular junction integrity and modulate immune signaling at the mucosal interface.

The key question the authors asked in this publication was whether supplementing LCA at physiological, human-relevant levels can directly protect human intestinal tissue from barrier disruption and inflammation.

The model: a human colitis-on-chip with epithelium, vasculature, and immune cells

Kaden and colleagues used a microphysiological intestine-on-chip to mimic central hallmarks of colitis while keeping the system human and experimentally controllable. The chip includes:

• Intestinal epithelium (Caco-2) forming villus- and crypt-like 3D structures under flow
• Vascular endothelium (HUVECs) on the opposing channel
• Human monocyte-derived macrophages integrated on the vascular side to capture immune–tissue crosstalk
• Colitis trigger: luminal perfusion with 1.5% dextran sodium sulfate (DSS) plus bacterial lipopolysaccharide (LPS) to induce barrier injury and microbial translocation
• Clinically relevant readouts: villus atrophy, barrier permeability (FITC-dextran), junction proteins (E-cadherin, ZO-1; VE-cadherin, CD31), cytokines (IL-6, TNF-α, IL-8, IL-1β), and epithelial proliferation (Ki-67)

Importantly, the system reproduced a colitis-like disease phenotype characterized by atrophied villus structures, increased permeability, disrupted junction networks in both epithelial and endothelial layers, and elevated pro-inflammatory cytokines. By directly comparing models with and without the presence of macrophages, the team could also pinpoint that these immune cells were the primary drivers of the underlying inflammation.

The intervention: physiological LCA protects barrier structure and function

The authors pre-treated the luminal side with LCA at 20 µM, chosen to match reported healthy human fecal concentrations and maintained it during DSS exposure. This is a crucial design choice: it tests a “restore what’s missing” hypothesis rather than applying supraphysiologic concentrations of pharmaceuticals.

• Preserved 3D tissue morphology: LCA prevented DSS-driven villus shortening/atrophy and maintained the architecture visible by live microscopy.
• Restored barrier integrity: LCA reduced DSS-induced leakiness (lower FITC-dextran permeability), bringing barrier function close to untreated controls.
• Protected junctional continuity in two compartments: LCA partially rescued epithelial junction markers (E-cadherin, ZO-1) and also improved endothelial adhesion/junction markers most notably increasing CD31 signal under inflammatory conditions.
• Dampened inflammatory output especially on the vascular side: vascular IL-6 and IL-8 were significantly reduced with LCA, and TNF-α trended lower. Effects in the intestinal compartment were more modest and cytokine-specific.
• Supported epithelial regeneration: DSS reduced Ki-67 (proliferation) in the epithelium; LCA significantly rescued proliferation to maintain barrier structure.

Mechanism signal: FXR is central to LCA’s protective effect in this human chip

LCA can bind multiple bile acid receptors, so the team probed two high-affinity candidates: the nuclear receptor FXR and the transmembrane receptor TGR5. When FXR was pharmacologically blocked (guggulsterone), LCA’s ability to preserve barrier integrity and epithelial proliferation was substantially diminished. In contrast, blocking TGR5 (SBI-115) did not meaningfully affect LCA-mediated barrier protection in this setup. Together, these results point to FXR-driven programs linked to junction maintenance and regenerative capacity as a dominant pathway for LCA’s benefit under colitis-like stress.

Why this matters (beyond one metabolite)

• A tractable way to test “postbiotic” hypotheses in humans: IBD dysbiosis is often discussed, but it’s hard to prove causality for specific metabolites. This work shows a direct, human-tissue-relevant protective effect of restoring a secondary bile acid that drops during active disease.
• Barrier repair as a therapeutic lever: Many therapies focus on suppressing immune activation. This paper highlights a complementary strategy: improve epithelial regeneration and junction integrity so fewer microbial cues cross into tissue and blood.
• FXR as a translational target: The data strengthen the rationale for targeting FXR-mediated pathways to preserve barrier function, either via bile acid analogs, receptor agonists, or approaches that restore secondary bile acid production.
• Organ-on-chip as a screening and mechanism platform: By integrating epithelium, endothelium, and macrophages under flow, the model captures multi-compartment effects (including vascular inflammation) that are invisible in simple monocultures and are difficult to dissect in animals.

Takeaway: In a human colitis-on-chip, physiological lithocholic acid meaningfully reduced colitis-like damage by maintaining villus morphology, tightening the barrier, and restoring epithelial proliferation, largely via FXR signaling. It’s a strong example of how microbiota-derived metabolites can be evaluated as mechanism-driven, human-relevant interventions.

Paper: Kaden T, Allwang M, Stallhofer J, Graf K, Raasch M, Mosig AS. Secondary bile acid lithocholic acid ameliorates colitis-like inflammation in a human intestine-on-chip system. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1761539

More interesting articles: